US 11,866,514 B2
Heterodimeric antibody Fc-containing proteins and methods for production thereof
Aran Frank Labrijn, Utrecht (NL); Joyce I. Meesters, Utrecht (NL); Ewald T. J. Van Den Bremer, Eindhoven (NL); Joost J. Neijssen, Werkhoven (NL); Patrick Van Berkel, Utrecht (NL); Bart De Goeij, Utrecht (NL); Tom Vink, Utrecht (NL); Jan Van De Winkel, Utrecht (NL); Janine Schuurman, Utrecht (NL); and Paul Parren, Odijk (NL)
Assigned to GENMAB A/S, Valby (DK)
Filed by GENMAB A/S, Valby (DK)
Filed on Jan. 30, 2020, as Appl. No. 16/777,053.
Application 16/777,053 is a division of application No. 15/414,122, filed on Jan. 24, 2017, granted, now 10,597,464.
Application 15/414,122 is a division of application No. 14/830,336, filed on Aug. 19, 2015, abandoned.
Application 14/830,336 is a continuation of application No. 13/642,253, granted, now 9,150,663, issued on Oct. 6, 2015, previously published as PCT/EP2011/056388, filed on Apr. 20, 2011.
Claims priority of provisional application 61/326,082, filed on Apr. 20, 2010.
Claims priority of application No. PA201000330 (DK), filed on Apr. 20, 2010; and application No. PA201001066 (DK), filed on Nov. 24, 2010.
Prior Publication US 2020/0262932 A1, Aug. 20, 2020
Int. Cl. C07K 16/46 (2006.01); C07K 16/10 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01); C07K 16/40 (2006.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/468 (2013.01) [C07K 16/1063 (2013.01); C07K 16/2809 (2013.01); C07K 16/2863 (2013.01); C07K 16/2887 (2013.01); C07K 16/32 (2013.01); C07K 16/40 (2013.01); G01N 33/6854 (2013.01); A61K 2039/505 (2013.01); C07K 2317/14 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/41 (2013.01); C07K 2317/526 (2013.01); C07K 2317/53 (2013.01); C07K 2317/55 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 37 Claims
 
1. A heterodimeric antibody comprising a first chimeric, humanized, or human heavy chain comprising a first Fc region, said first Fc region comprising a first CH3 region of human IgG4, and a second chimeric, humanized, or human heavy chain comprising a second Fc region, said second Fc region comprising a second CH3 region of human IgG4 comprising amino acid substitutions at positions 405 and 409, wherein the numbering is according to the EU Index, and wherein the sequences of the first and second CH3 regions are different.